Teacher Retirement System of Texas cut its stake in Mylan N.V. (NASDAQ:MYL) by 60.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 182,787 shares of the company’s stock after selling 279,221 shares during the period. Teacher Retirement System of Texas’ holdings in Mylan were worth $5,734,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. increased its position in Mylan by 76.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after acquiring an additional 1,475 shares during the period. BT Investment Management Ltd acquired a new position in Mylan in the 3rd quarter valued at about $142,000. Global X Management Co. LLC increased its position in Mylan by 59.2% in the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after acquiring an additional 1,786 shares during the period. Doliver Capital Advisors LP acquired a new position in Mylan in the 2nd quarter valued at about $201,000. Finally, Eagle Global Advisors LLC acquired a new position in Mylan in the 2nd quarter valued at about $205,000. Hedge funds and other institutional investors own 73.86% of the company’s stock.
Shares of Mylan N.V. (NASDAQ:MYL) traded down $0.68 during trading on Monday, reaching $37.44. 5,736,114 shares of the company were exchanged, compared to its average volume of 5,949,534. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The stock has a market cap of $20,450.00, a PE ratio of 8.11, a price-to-earnings-growth ratio of 2.09 and a beta of 1.38.
Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.38 earnings per share. analysts predict that Mylan N.V. will post 4.56 earnings per share for the current year.
A number of equities research analysts have weighed in on the company. Citigroup raised Mylan from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $36.00 to $42.00 in a report on Wednesday, August 16th. Royal Bank Of Canada reissued a “sector perform” rating and set a $32.00 price target (down previously from $33.00) on shares of Mylan in a research note on Thursday, August 10th. Cowen reissued a “hold” rating and set a $30.00 price target (down previously from $43.00) on shares of Mylan in a research note on Wednesday, August 9th. Wells Fargo & Company set a $32.00 price target on Mylan and gave the stock a “hold” rating in a research note on Wednesday, October 4th. Finally, UBS set a $46.00 price objective on Mylan and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $41.49.
TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/mylan-n-v-myl-shares-sold-by-teacher-retirement-system-of-texas.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.